Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Effect of Physical ACtivity in Fingolimod Treated patiEnts (PACE) With Relapsing-remitting Multiple Sclerosis (PACE)

This study has been terminated.
(The study stopped due to slow enrollment and low participant compliance.)
Sponsor:
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )
ClinicalTrials.gov Identifier:
NCT01490840
First received: December 9, 2011
Last updated: April 7, 2016
Last verified: April 2016
  Purpose
This study evaluated the effect of an individualized web-based physical training in fingolimod -treated patients.

Condition Intervention Phase
Fatigue in Multiple Sclerosis
Other: Physical exercise
Phase 4

Study Type: Interventional
Study Design: Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A 6-month, Multicenter, Randomized, Controlled Parallel Group Study to Evaluate the Effect of Physical Training on Fatigue in Patients With Relapsing-remitting Multiple Sclerosis Treated With Fingolimod, Followed by a 6 Month Optional Extension Phase

Resource links provided by NLM:


Further study details as provided by Novartis:

Primary Outcome Measures:
  • Change From Baseline in Fatigue as Measured by the Modified Fatigue Impact Scale (mFIS ). [ Time Frame: Baseline, 6 months ] [ Designated as safety issue: No ]
    The mFIS provides an assessment of the effects of fatigue in terms of physical, cognitive, and psychosocial functioning. It is a 21-item, structured, self-report questionnaire that generally can be completed with little or no intervention from an interviewer. The mFIS score ranged from 0 (not tired) to 84 (tired). A negative change from baseline indicates improvement.


Secondary Outcome Measures:
  • Change From Baseline in Isometric and Dynamic Muscular Strength as Measured by Sit-to-stand Test [ Time Frame: baseline, 6 months ] [ Designated as safety issue: No ]
    The Sit to Stand Test is a functional outcome measure of the lower-extremity muscle power. The test was performed 3 times with one minute rest in between. The best attempt out of three was used for the analysis. A positive change from baseline indicates improvement.

  • Change From Baseline in Isometric and Dynamic Muscular Strength as Measured by Change in Leg Strength and Trunk Strength [ Time Frame: baseline, 6 months ] [ Designated as safety issue: No ]

    Isometric and dynamic muscular strength was measured by an Isomed 2000 isometric measurement device (knee flexion/tension, trunk flexion/extension).

    Isomed 2000 device measures muscular flexion and tension under standardized training conditions. A positive change from baseline indicates improvement.


  • Change From Baseline in Isometric and Dynamic Muscular Strength as Measured by Leg Strength Endurance [ Time Frame: baseline, 6 months ] [ Designated as safety issue: No ]

    Isometric and dynamic muscular strength was measured by an Isomed 2000 isometric measurement device (knee flexion/tension, trunk flexion/extension).

    Isomed 2000 device measures muscular flexion and tension under standardized training conditions. A positive change from baseline indicates improvement.


  • Change From Baseline in Quality of Life as Measured by the Hamburg Quality of Life Questionnaire in Multiple Sclerosis (HAQUAMS) [ Time Frame: Baseline, 6 months, 12 months ] [ Designated as safety issue: No ]
    The Hamburg Quality of Life Questionnaire in Multiple Sclerosis (HAQUAMS) consists of 44 items, 28 of which are the basis for computation of five subscale scores reflecting major dimensions of health-related quality of life (HRQoL) in MS: Fatigue/Thinking (4 items), Mobility lower limb (5 items), Mobility upper limb (5 items), Social function (6 items) and Mood (eight items). Subscales and total score range from 1 to 5, with high scores indicating a lower quality of life. In this study, the total score and following 3 subscales: fatigue/thinking, mobility lower limb and mobility upper limb only were analyzed. A negative change from baseline indicates improvement.

  • Change From Baseline in Fatigue as Measured by the WEIMuS (Würzburg Fatigue Inventory for MS) [ Time Frame: Baseline, 6 months ] [ Designated as safety issue: No ]
    The WEIMuS (Würzburg Fatigue Inventory for MS) scale is a validated self-assessment instrument to quantify the degree of fatigue. The scale consists of 17 items with 5 categories that are scored from '0' to '4'. The subscores for cognitive and physical fatigue range from 0 to 36 and from 0 to 32, respectively, with the total sum score ranging from 0 to 68; higher scores indicate higher degrees of fatigue. A negative change from baseline indicates improvement.

  • Change From Baseline in Depression as Measured by the Beck Depression Inventory Second Edition (BDI-II) [ Time Frame: Baseline, 6 months ] [ Designated as safety issue: No ]
    The Beck Depression Inventory Second Edition (BDI-II) is a 21-item self-report instrument intended to assess the existence and severity of symptoms of depression as listed in the American Psychiatric Association's Diagnostic and Statistical Manual of Mental Disorders Fourth Edition. Each of the 21 items corresponding to a symptom of depression is summed to give a single score for the BDI-II. There is a four-point scale for each item ranging from 0 to 3. The total score ranges from 0 - 63. Total score of 0-13 is considered minimal range, 14-19 is mild, 20-28 is moderate, and 29-63 is severe. A negative change from baseline indicates improvement.

  • Change From Baseline in Aerobic Capacity (VO2max) as Measured by a Physical Endurance Spiroergometry on a Treadmill [ Time Frame: Baseline, 6 months ] [ Designated as safety issue: No ]
    Physical endurance spiroergometry was accomplished. Ergometry was assessed according to national guidelines of the German society for sports medicine. Ergometry is a combined examination of circulation and lung function and was performed as a submaximal or maximal test depending on the participant's individual performance. A negative change from baseline indicates improvement.

  • Change From Baseline in Peak Expiratory Flow as Measured by a Physical Endurance Spiroergometry on a Treadmill [ Time Frame: Baseline, 6 months ] [ Designated as safety issue: No ]
    Physical endurance spiroergometry was accomplished. Ergometry was assessed according to national guidelines of the German society for sports medicine. Ergometry is a combined examination of circulation and lung function and was performed as a submaximal or maximal test depending on the participant's individual performance. A positive change from baseline indicates improvement.


Enrollment: 178
Study Start Date: November 2011
Study Completion Date: July 2014
Primary Completion Date: July 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: E-training
Fingolimod as baseline immunomodulatory multiple sclerosis treatment was prescribed as per clinical practice. During phase 1, participants randomized to this arm had an introductory group session, hosted by a sports therapist. The individual training schedule was comprised of strength exercises twice a week for 30-45 minutes and endurance training once a week for 20-60 minutes for 6 months. The participants documented each training session thoroughly via the web-based application (duration, type of exercises, number of repetitions and sets, perceived exertion). A standard course of corticosteroids (methylprednisolone) on an inpatient or outpatient basis was allowed for treatment of relapses as clinically warranted. Steroid treatment consisted of 3-5 days and up to 1,000 mg methylprednisolone/day. After 6 months, Phase 2, the same Phase 1 regimen applied.
Other: Physical exercise
Strength training exercises are performed against own body weight or with training aids like elastic rubber bands or gym balls. All exercises are home-based. To increase balance and core stability, a subset of exercises is performed on shaky ground and/or one-legged. Exercise intensity, duration and frequency are individually assigned by a sports therapist. For each muscle group, a set of exercises of increasing difficulty allows for individual and progressive training adaption. Therapists can choose from an exercise database of approximately 150 different strength exercises with different graduation.
Experimental: Waiting
Fingolimod as baseline immunomodulatory multiple sclerosis treatment is prescribed as per clinical practice. During Phase 1, participants randomized to this arm did not receive e-training exercise. After a 6 months waiting period, phase 2, participants had an introductory group session, hosted by a sports therapist. The individual training schedule was comprised of strength exercises twice a week for 30-45 minutes and endurance training once a week for 20-60 minutes for 6 months. The participants documented each training session thoroughly via the web-based application (duration, type of exercises, number of repetitions and sets, perceived exertion). A standard course of corticosteroids (methylprednisolone) on an inpatient or outpatient basis was allowed for treatment of relapses as clinically warranted. Steroid treatment consisted of 3-5 days and up to 1,000 mg methylprednisolone/day.
Other: Physical exercise
Strength training exercises are performed against own body weight or with training aids like elastic rubber bands or gym balls. All exercises are home-based. To increase balance and core stability, a subset of exercises is performed on shaky ground and/or one-legged. Exercise intensity, duration and frequency are individually assigned by a sports therapist. For each muscle group, a set of exercises of increasing difficulty allows for individual and progressive training adaption. Therapists can choose from an exercise database of approximately 150 different strength exercises with different graduation.

Detailed Description:
In this study, it was planned to randomize 226 participants. However, only 178 participants were randomized during a timeframe of 2 years and 8 months. Therefore, the study was terminated due to slow enrollment and low participant compliance to the physical training schedule.
  Eligibility

Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subjects with relapsing remitting MS defined by 2010 revised McDonald criteria
  • Patients with Expanded Disability Status Scale (EDSS) score of 0-3.5 (including)
  • Immunomodulatory treatment with prescribed fingolimod for at least one month prior to baseline
  • Fatigue score assessed by mFIS of equal or greater than 14 at screening
  • Neurologically stable with no evidence of relapse within 30 days prior to inclusion date

Exclusion Criteria:

  • Patients who have been treated with:

    • systemic corticosteroids or immunoglobulins within 1 month prior to randomization;
    • immunosuppressive medications such as azathioprine, cyclophosphamide, or methotrexate within 3 months prior to randomization;
    • monoclonal antibodies (including natalizumab) within 3 months prior to randomization;
    • mitoxantrone within 6 months prior to randomization
    • cladribine at any time.
  • Patients with any medically unstable condition, as assessed by the primary treating physician at each site.
  • Patients with any of the following cardiovascular conditions :

    • history of cardiac arrest;
    • history of myocardial infarction or with current unstable ischemic heart disease;
    • history of angina pectoris due to coronary spasm or history of Raynaud syndrome
    • Heart failure (NYHA III-IV) or any severe cardiac disease as determined by the investigator;
    • history or presence of a second-degree AV block, Type II or a third-degree AV
    • block
    • patients receiving Class Ia (ajmaline, disopyramide, procainamide, quinidine) or
    • III antiarrhythmic drugs (e.g., amiodarone, bretylium, sotalol, ibulitide, azimilide,
    • dofelitide);
    • proven history of sick sinus syndrome or sino-atrial heart block;
    • uncontrolled hypertension
  • Clinically relevant internal disease (e.g. uncorrected anemia) or orthopedic diseases (e.g. scoliosis) that might interfere with physical training
  • Any severe disability or clinical impairment that can prevent the patient to meet all study requirements at the investigator`s discretion

Other protocol-defined inclusion/exclusion criteria may apply.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01490840

Locations
Germany
Novartis Investigative Site
Aachen, Germany, 52062
Novartis Investigative Site
Alzenau, Germany, 63755
Novartis Investigative Site
Aschaffenburg, Germany, 63739
Novartis Investigative Site
Bad Mergentheim, Germany, 97980
Novartis Investigative Site
Bamberg, Germany, 96052
Novartis Investigative Site
Bayreuth, Germany, 95445
Novartis Investigative Site
Berlin, Germany, 10437
Novartis Investigative Site
Berlin, Germany, 10625
Novartis Investigative Site
Berlin, Germany, 10691
Novartis Investigative Site
Berlin, Germany, 12587
Novartis Investigative Site
Berlin, Germany, 13347
Novartis Investigative Site
Bielefeld, Germany, 33647
Novartis Investigative Site
Bochum, Germany, 44787
Novartis Investigative Site
Böblingen, Germany, 71032
Novartis Investigative Site
Dortmund, Germany, 44135
Novartis Investigative Site
Erbach, Germany, 64711
Novartis Investigative Site
Erlangen, Germany, 91054
Novartis Investigative Site
Frankfurt, Germany, 65929
Novartis Investigative Site
Hamburg, Germany, 22179
Novartis Investigative Site
Heidelberg, Germany, 69120
Novartis Investigative Site
Jena, Germany, 07740
Novartis Investigative Site
Kassel, Germany, 34121
Novartis Investigative Site
Leipzig, Germany, 04299
Novartis Investigative Site
Potsdam, Germany, 14471
Novartis Investigative Site
Prien, Germany, 83209
Novartis Investigative Site
Regensburg, Germany, 93053
Novartis Investigative Site
Siegen, Germany, 57076
Novartis Investigative Site
Sinsheim, Germany, 74889
Novartis Investigative Site
Stuttgart, Germany, 70174
Novartis Investigative Site
Stuttgart, Germany, 70178
Novartis Investigative Site
Teupitz, Germany, 15755
Novartis Investigative Site
Unterhaching, Germany, 82008
Sponsors and Collaborators
Novartis Pharmaceuticals
Investigators
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals
  More Information

Responsible Party: Novartis Pharmaceuticals
ClinicalTrials.gov Identifier: NCT01490840     History of Changes
Other Study ID Numbers: CFTY720DDE07  2011-002969-38 
Study First Received: December 9, 2011
Results First Received: July 10, 2015
Last Updated: April 7, 2016
Health Authority: United States: Food and Drug Administration
Germany: Ministry of Health

Keywords provided by Novartis:
Fatigue
MS
Multiple Sclerosis
Exercise
Physical activity
Physical training
Fingolimod

Additional relevant MeSH terms:
Sclerosis
Multiple Sclerosis
Fatigue
Multiple Sclerosis, Relapsing-Remitting
Pathologic Processes
Demyelinating Autoimmune Diseases, CNS
Autoimmune Diseases of the Nervous System
Nervous System Diseases
Demyelinating Diseases
Autoimmune Diseases
Immune System Diseases
Signs and Symptoms
Methylprednisolone
Fingolimod Hydrochloride
Anti-Inflammatory Agents
Antiemetics
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Gastrointestinal Agents
Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Neuroprotective Agents
Protective Agents
Immunosuppressive Agents
Immunologic Factors

ClinicalTrials.gov processed this record on September 29, 2016